metabolism of purine nucleotides 1- biosynthesis of purine nucleoetides a- de novo biosynthesis (10...

22
Metabolism of purine nucleotides 1- Biosynthesis of purine nucleoetides A- De novo biosynthesis (10 % in liver mainly) B- Salvage pathway (90 % in other tissues) 2- Degradation of purine nucleotides 3- Disorders of purine nucleotides A- Gout B- Lesch Nyhan syndrome

Upload: arleen-mitchell

Post on 20-Jan-2016

265 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: Metabolism of purine nucleotides 1- Biosynthesis of purine nucleoetides A- De novo biosynthesis (10 % in liver mainly) B- Salvage pathway (90 % in other

Metabolism of purine nucleotides

1- Biosynthesis of purine nucleoetidesA- De novo biosynthesis (10 % in liver mainly)

B- Salvage pathway (90 % in other tissues)

2- Degradation of purine nucleotides

3- Disorders of purine nucleotides A- Gout B- Lesch Nyhan syndrome

Page 2: Metabolism of purine nucleotides 1- Biosynthesis of purine nucleoetides A- De novo biosynthesis (10 % in liver mainly) B- Salvage pathway (90 % in other

2

Remember that purine nucleotides are:

AMP, ADP , ATP: adenosine mono (or di or tri) phosphate

GMP, GDP, GTP: Guanosine mono (or di or tri) phosphate

Page 3: Metabolism of purine nucleotides 1- Biosynthesis of purine nucleoetides A- De novo biosynthesis (10 % in liver mainly) B- Salvage pathway (90 % in other

3

A- De Novo synthesis of AMP and GMP

Site: Mainly in the liver (in the cytoplasm)

Sources of the atoms in purine ring:

• N1: derived from NH2 group of aspartate• C2 and C8: from formate group• N3 and N9 : amide group of glutamine• C4, C5 , N7: glycine amino acid• C6: from CO2

3

Page 4: Metabolism of purine nucleotides 1- Biosynthesis of purine nucleoetides A- De novo biosynthesis (10 % in liver mainly) B- Salvage pathway (90 % in other

4

Page 5: Metabolism of purine nucleotides 1- Biosynthesis of purine nucleoetides A- De novo biosynthesis (10 % in liver mainly) B- Salvage pathway (90 % in other

5

Notes on de novo purine nucleotides biosynthesis:

1.Phosphoribosyl pyrophosphate (PRPP) is the source of ribose -

5-phosphate. PRPP is the active form of ribose-5-phosphate

2.Pyrophosphate is removed from PRPP and substituted with NH2

group of glutamine to form phosphoribosylamine. This step is the

rate limiting step and catalyzed by amidophosphoribosyl

transferase

Page 6: Metabolism of purine nucleotides 1- Biosynthesis of purine nucleoetides A- De novo biosynthesis (10 % in liver mainly) B- Salvage pathway (90 % in other

6

The rate limiting step in de novo biosynthesis

Page 7: Metabolism of purine nucleotides 1- Biosynthesis of purine nucleoetides A- De novo biosynthesis (10 % in liver mainly) B- Salvage pathway (90 % in other

7

3. The ring is then formed from their atoms sources (aspartic, glutamine, glycine, etc).

4. The pathway ends with the formation of a purine nucleotide called : Inosine monophosphate (IMP) which is the precursor of AMP and GMP which then converted into ATP and GTP, respectively

←AMP and GMP

Page 8: Metabolism of purine nucleotides 1- Biosynthesis of purine nucleoetides A- De novo biosynthesis (10 % in liver mainly) B- Salvage pathway (90 % in other

8

NB: IMP is a nucleotide contain purine base which is hypoxanthine (6 –oxy purine). Hypoxanthine is a purine base not enter in DNA or RNA structure

hypoxanthine

8

Page 9: Metabolism of purine nucleotides 1- Biosynthesis of purine nucleoetides A- De novo biosynthesis (10 % in liver mainly) B- Salvage pathway (90 % in other

9

IMP is converted into AMP by the addition of aspartate. NH2 group of aspartate replace oxy group in carbon 6 to form AMP.

IMP is converted into GMP through the addition of glutamine. NH2 group of glutamine is added to carbon 2 to form GMP.

6

2

Page 11: Metabolism of purine nucleotides 1- Biosynthesis of purine nucleoetides A- De novo biosynthesis (10 % in liver mainly) B- Salvage pathway (90 % in other

11

Regulation of the pathway:

amidophosphoribosyl transferase catalyses the rate limiting step

of the pathway.

Activator of the amidotransferase:

This enzyme is activated by PRPP.

So PRPP is an activator of the pathway. Increased PRPP leads to

overproduction of purine nucleotides.

Inhibitors of the amidotransferase:

The enzyme is inhibited by the final products of the pathway (IMP,

AMP and GMP).

Page 12: Metabolism of purine nucleotides 1- Biosynthesis of purine nucleoetides A- De novo biosynthesis (10 % in liver mainly) B- Salvage pathway (90 % in other

1212

B- Salvage pathway of purines: or resynthesis of purine nucleotides:

De novo biosynthesis occur in liver due to presence of enzymes. Other

tissues can’t do de novo synthesis. In these organs, free purine bases

(guanine, hypoxanthine and adenine) reacts with PRPP again to

resynthesize purine nucleotides.

These free purine bases are obtained from diet or result during

breakdown of purine nucleotides (see purine catabolism)

Page 13: Metabolism of purine nucleotides 1- Biosynthesis of purine nucleoetides A- De novo biosynthesis (10 % in liver mainly) B- Salvage pathway (90 % in other

1313

Salvage pathway needs two enzymes:

1- Adenine phosphoribosyl transferase (APRTase)

2- Hypoxanthine-guanine phosphoribosyl transferase (HGPRTase)

Both enzymes use PRPP as the source of ribose-5-phosphate

The first enzyme catalyze the transfer of ribose-5-P from PRPP to adenine to synthesize AMP.

Adenine + PRPP → AMPAPRTase

Page 14: Metabolism of purine nucleotides 1- Biosynthesis of purine nucleoetides A- De novo biosynthesis (10 % in liver mainly) B- Salvage pathway (90 % in other

14

The second salvage enzyme (HGPRTase) catalyzes the transfer of ribose-5-P into hypoxanthine or guanine to regenerate IMP or GMP.

Hypoxanthine + PRPP → IMP

Guanine + PRPP → GMP

HGPRTase

HGPRTase

Page 15: Metabolism of purine nucleotides 1- Biosynthesis of purine nucleoetides A- De novo biosynthesis (10 % in liver mainly) B- Salvage pathway (90 % in other

Catabolism (breakdown) of purine nucleotides

Uric acid is the end product of purine metabolism in human.

AMP or GMP is metabolized to give hypoxanthine which is then

converted into xanthine and finally into uric acid as in the next slide.

Most of uric acid is excreted by the kidney. The remaining uric acid

travels through the intestines, where bacteria help break it down.

Normally these actions keep the level of uric acid in the blood plasma

at a healthy level, which is below 6.8 mg/dL. But under certain

circumstances, the body produces too much uric acid or removes too

little. In either case, concentrations of uric acid increase in the blood.

This condition is known as hyperuricemia.15

Page 16: Metabolism of purine nucleotides 1- Biosynthesis of purine nucleoetides A- De novo biosynthesis (10 % in liver mainly) B- Salvage pathway (90 % in other

16

Page 17: Metabolism of purine nucleotides 1- Biosynthesis of purine nucleoetides A- De novo biosynthesis (10 % in liver mainly) B- Salvage pathway (90 % in other

17

Disorders of purine nucleotides metabolism

A- Gout: is a disorder characterized by high levels of uric acid in blood (hyperuricemia), with deposition of monosodium urate crystals in special sites in the body like joints, and surrounding tissues and sometimes in the kidney. Gout is a type of arthritis

Urate crystals are detected in synovial fluid of the joint

Page 18: Metabolism of purine nucleotides 1- Biosynthesis of purine nucleoetides A- De novo biosynthesis (10 % in liver mainly) B- Salvage pathway (90 % in other

Causes: Primary causes such as1- decreased excretion of uric acid by the kidney due to renal disease,

Sometimes it is inherent.2-defect in purine metabolism: increased synthesis of purine

nucleotides which may be idiopathic (with unknown cause) or due to increased levels of PRPP that stimulate synthetic pathway of purine nucleotides. The increased purine lead to increased uric acid production

Secondary causes: such as diet rich in purines such as red meat, duck, liver, xanthine beverages like tea, coffee, cola or due to medication

Symptoms: 1- Hyperuricemia: increased uric acid levels in blood 2- arthritis, inflammation especially in joints due to deposition of urate crystals leading to hot red and swollen joints with severe pain. 3- redness, swelling of big toe.

18

Page 19: Metabolism of purine nucleotides 1- Biosynthesis of purine nucleoetides A- De novo biosynthesis (10 % in liver mainly) B- Salvage pathway (90 % in other

4- it may also present as tophi (masses of urate crystals deposited under skin) appears after several years.

5- It may lead to kidney stones,

Tophi, in chronic cases, lumpy deposits of urate just under the skin 19

Page 20: Metabolism of purine nucleotides 1- Biosynthesis of purine nucleoetides A- De novo biosynthesis (10 % in liver mainly) B- Salvage pathway (90 % in other

Treatment: Allopurinol, analogue of hypoxanthine (structurally similar). It competitively inhibits xanthine oxidase, so prevents the conversion of hypoxanthine to xanthine and xanthine to uric acid.

Uricosuric agents: drugs used to increase excretion of uric acid by the kidney such as probenecid.

Anti-inflammatory drugs is recommended also.20

Page 21: Metabolism of purine nucleotides 1- Biosynthesis of purine nucleoetides A- De novo biosynthesis (10 % in liver mainly) B- Salvage pathway (90 % in other

21

Page 22: Metabolism of purine nucleotides 1- Biosynthesis of purine nucleoetides A- De novo biosynthesis (10 % in liver mainly) B- Salvage pathway (90 % in other

22

B-Lesch –Nyhan syndrome:

Cause: inherited disease resulting from complete deficiency (absesnce) of HGPRTase → block (inhibit) salvage pathway of guanine and hypoxanthine → ↓ use of PRPP in salvage pathway and ↑ its use in purine synthesis leading to overproduction of purine nucleotides which by catabolism, will give increased levels of uric acid

Symptoms: appear at age 3-6 months. The first symptom is orange colored crystals in the diaper of the baby.

1- Hyperuricemia: in aggressive way than in gout.2- urate kidney stones:Some symptoms of unknown mechanism are:3- mental retardation4- involuntary movements of legs and arms5- lack of muscle coordination6- self mutilation (biting of fingers and lipsleading to lip lesions). 22